Introducing zelasudil, our investigational next-generation selective ROCK2 inhibitor. For more information, please visit: https://lnkd.in/eRETdXTw
Redx Pharma
Pharmaceutical Manufacturing
Alderley Park, Macclesfield 12,082 followers
Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis
About us
Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for idiopathic pulmonary fibrosis and commenced a Phase 2 clinical trial in Q4 2022. Redx’s second ROCK inhibitor candidate, RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, commenced a Phase 1 clinical trial in Q1 2024. The Company's lead oncology product candidate, the Porcupine inhibitor, zamaporvint (RXC004), commenced a Phase 2 programme in November 2021. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. Read more about our company at https://www.redxpharma.com/about-us/ If you're interested in joining us, please visit https://www.redxpharma.com to see what job vacancies we currently have.
- Website
-
http://redxpharma.com
External link for Redx Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Alderley Park, Macclesfield
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Oncology, Fibrosis, Pharmaceuticals, Drug Discovery and Development, and Biotech
Locations
-
Primary
Get directions
Block 33
Mereside
Alderley Park, Macclesfield SK10 4TG, GB
Employees at Redx Pharma
Updates
-
Without Clinical trials, we simply would not be able to make medicines for people. We’d like to take a moment to thank our highly skilled Redx Pharma Clinical Trial teams for their expertise in clinical trial design, management and delivery of these complex programmes. #ClinicalTrialDay #FibrostenoticCrohn’s #Crohn’sDisease #IBD
-
-
The Redx Pharma team held a fundraiser bake sale today to mark World IBD Day 2025 and support the work of Crohn's & Colitis UK. Redx Pharma is focused on the development of a treatment to help people with fibrostenotic Crohn’s Disease, a potentially lifelong illness, who remain without available targeted therapies. #WorldIBDDay #FibrostenoticCrohn’s #Crohn’sDisease #Colitis #IBD
-
-
Congratulations to the Redx Pharma team on another fantastic Phase 1 data update on RXC008 at DDW2025. A team effort by everyone at Redx Pharma! For more information, please click https://bit.ly/4jYLncC #DDW2025 #FibrostenoticCrohn’s #Crohn’sDisease #IBD #DrugDevelopment
-
-
Redx Pharma's Expert Advisor Dr Florian Rieder, M.D., Vice Department Chair, Co-Section Director Inflammatory Bowel Diseases, Director Cleveland Clinic Program for Global Translational Inflammatory Bowel Diseases, Cleveland Clinic, USA, will be onsite for DDW2025 to present further new phase 1 data for RXC008, a potential first-in-class treatment for fibrostenotic Crohn’s disease #DDW2025 #FibrostenoticCrohn’s #Crohn’sDisease #IBD #DrugDevelopment
-
-
Redx Pharma’s Dr Helen Timmis, Interim Chief Medical Officer is heading to DDW2025 in San Diego this weekend to participate in the latest discussions and presentations concerning the urgent need for treatments in fibrostenotic Crohn’s disease #DDW2025 #FibrostenoticCrohn’s #Crohn’sDisease #IBD #DrugDevelopment
-
-
Congratulations to Redx Pharma's Dr Nicolas Guisot, Vice President, Head of Development Science and the Redx BTK team on winning The Royal Society of Chemistry’s Biological and Medicinal Sector, Malcolm J. Campbell Memorial Prize for 2025! For more information, please click here https://bit.ly/4hxpkIz #BMCS #lymphoma #leukemia
-
-
Redx Pharma is here in Milan, ready and excited for Bio-Europe Spring 2025! #BIOEuropeSpring #Lifescience #Biotech
-
-
Redx Pharma's James Barwell, Head of Business Development will be heading to Bio-Europe Spring this weekend. Look forward to seeing you in Milan! #BIOEuropeSpring #Lifescience #Biotech
-
-
Congratulations to the Redx Pharma team on a fantastic presentation at ECCO2025. A team effort by everyone at Redx Pharma! For more information, please click https://bit.ly/4bekiiq #ECCO2025 #FibrostenoticCrohn’s #Crohn’sDisease #IBD #DrugDevelopment
-